← Back to patent-cliff list
Zilebesiran
Tier C — Watch / tradeZilebesiran
Alnylam Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：AGT
Indications (approved)：Hypertension, Cardiac and vascular disorders, 先兆子痫
Regional status
US
Phase III
2025-09-22
EU
Phase III
2025-09-22
China
Phase III
2025-09-22
Japan
Phase III
2025-09-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zilebesiran?
Approved indications include: Hypertension, Cardiac and vascular disorders, 先兆子痫.
When does the Zilebesiran patent expire?
No public expiry year is available for Zilebesiran yet; this page updates once verified.
How do I get a quote for Zilebesiran intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30